Equities research analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.
Bio-Path Stock Performance
BPTH stock opened at $0.71 on Monday. The firm’s 50-day moving average is $0.94 and its two-hundred day moving average is $1.43. Bio-Path has a 52 week low of $0.61 and a 52 week high of $12.00.
Hedge Funds Weigh In On Bio-Path
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors own 5.74% of the company’s stock.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More
- Five stocks we like better than Bio-Path
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Netflix Is On Track To Hit $1,000 By Christmas
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
